“During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “The company is now well positioned for growth with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years. Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026. We see emerging high-value potential in our obesity and CNS programs entering early clinical studies. Arrowhead is currently funded into 2028 with further cash runway potential with multiple wholly owned candidates providing opportunities for additional partnerships.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead to receives $500M upfront in licensing pact with Sarepta
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 Earnings Cheat Sheet
- Arrowhead Pharmaceuticals Appoints Douglas Ingram as Director
- Genelux names Matthew Pulisic as CFO, effective January 30
- Closing Bell Movers: Electronic Arts down over 10% on guidance cut